Zepbound vs. Mounjaro: Which Is Better? Side-by-Side Comparison

Which is better, Zepbound or Mounjaro? If your main goal is to lose weight and keep it off, Zepbound is generally the better choice because it’s specifically FDA-approved for chronic weight management. However, if your main goal is to control blood sugar while managing type 2 diabetes, Mounjaro is generally the better option because it’s specifically approved for diabetes treatment.

But there’s an interesting twist: Zepbound and Mounjaro contain exactly the same active ingredient, tirzepatide, and are made by the same manufacturer, Eli Lilly. That means neither medication is inherently more powerful than the other at equivalent doses.

So, which one should you choose? If you’re managing obesity or overweight and need substantial weight loss, Zepbound may be the better fit. It also has an additional advantage for adults with obesity and moderate to severe obstructive sleep apnea. Mounjaro, on the other hand, is designed for people with type 2 diabetes who need better blood sugar control, with weight loss as an additional potential benefit.

Ultimately, the best choice depends on your medical history, treatment goals, insurance coverage, and eligibility. Since both medications contain tirzepatide, they should not be taken together.

DFWPMA offers in-person GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications at a DFWPMA location across Texas to eligible patients when medically appropriate, subject to medication availability.

Our primary care providers and endocrinologists also offer ongoing care to monitor potential side effects, address health concerns, and support patients throughout GLP-1 treatment. DFWPMA does not currently offer online GLP-1 prescriptions, an in-person evaluation is required.

Book an appointment online or call (903) 957-0082 to contact our scheduling team.

Get Prescriptions for GLP-1 Medications at a DFWPMA Location Near You!

📍 GLP-1 Prescription Providers in Fort Worth, TX

1220 W Presidio St, Fort Worth, TX 76102

Book an Appointment at Our Fort Worth Location →
📍 GLP-1 Prescription Providers in Frisco, TX

7589 Preston Rd., Suite 900, Frisco, TX 75034

Book an Appointment at Our Frisco Location →
📍 GLP-1 Prescription Providers in Sherman, TX

425 N Highland Ave., Suite 260, Sherman, TX 75092

Book an Appointment at Our Sherman Location →
📞 Call DFWPMA to Schedule

Speak with our scheduling team about GLP-1 prescription evaluations, provider availability, and appointments.

Call Us → (903) 957-0082

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

What Is Zepbound?

Zepbound (tirzepatide) is a prescription medication FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related medical condition. It is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity.

Zepbound activates two hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action helps regulate appetite, reduce food intake, and promote substantial weight loss. Although tirzepatide also improves blood sugar regulation, Zepbound is not specifically FDA-approved to treat type 2 diabetes.

Zepbound

What Is Mounjaro?

Mounjaro (tirzepatide) is a prescription dual GIP and GLP-1 receptor agonist approved to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. It also has an FDA-approved cardiovascular risk-reduction indication for eligible adults with type 2 diabetes at high cardiovascular risk.

Mounjaro works by improving glucose-dependent insulin secretion, reducing glucagon secretion, and helping regulate appetite and food intake. It can also produce substantial weight loss, although Mounjaro is not FDA-approved specifically for chronic weight management. Its active ingredient is identical to Zepbound’s.

Zepbound vs. Mounjaro: Side by Side Comparison

Zepbound and Mounjaro contain the same active ingredient, tirzepatide, and work through the same GIP and GLP-1 receptor mechanisms. Their biggest differences are their FDA-approved indications, clinical trial populations, insurance coverage, and manufacturer pricing programs. Zepbound is primarily prescribed for weight management and qualifying sleep apnea, while Mounjaro is primarily prescribed for type 2 diabetes.

ComparisonZepboundMounjaro
ManufacturerEli Lilly and CompanyEli Lilly and Company
PricingManufacturer self-pay options:

 

  • Starting Dose: $299/month for 2.5 mg through eligible KwikPen or vial self-pay programs.
  • 5 mg Dose: $399/month through eligible self-pay options.
  • Higher Doses: As low as $449/month for 7.5 mg, 10 mg, 12.5 mg, or 15 mg with the Zepbound Self Pay Journey Program.
  • Program Requirements: Higher-dose promotional pricing requires eligible refills within 45 days; otherwise, regular prices may apply.

Retail prices may be higher.

Manufacturer pricing and savings:

 

  • Self-Pay Price: Starting at $499/month through eligible LillyDirect purchasing options.
  • Available Doses: Self-pay offers apply to listed doses from 2.5 mg through 15 mg, subject to program terms.
  • Insurance Savings: Eligible commercially insured patients with coverage may pay as little as $25 for a qualifying prescription.

Actual pharmacy prices may vary.

Insurance Coverage
  • Commercial Insurance: Some plans cover Zepbound for eligible patients with obesity or other approved indications.
  • Prior Authorization: BMI, weight-related conditions, and medical documentation may be required.
  • Medicare: Coverage depends on the approved indication, applicable program rules, and individual plan. Some patients may qualify for the Medicare GLP-1 Bridge program.
  • Diabetes Alone: Zepbound is not specifically approved for type 2 diabetes treatment.
  • Commercial Insurance: Many plans cover Mounjaro for eligible patients with type 2 diabetes.
  • Medicare Part D: Coverage may be available for eligible beneficiaries with type 2 diabetes.
  • Prior Authorization: A diabetes diagnosis and supporting medical documentation may be required.
  • Weight Loss Alone: Generally not covered because Mounjaro is not approved specifically for weight management.
Main PurposeLong-term weight loss and weight maintenance in eligible adults with obesity or overweight.Improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes.
Secondary Purposes
  • Sleep Apnea: Treat moderate to severe obstructive sleep apnea in adults with obesity.
  • Metabolic Health: May improve blood sugar regulation and other metabolic measures.
  • Cardiovascular Protection: Reduce major cardiovascular events in eligible adults with type 2 diabetes at high cardiovascular risk.
  • Weight Reduction: May produce substantial weight loss as an additional treatment effect, although chronic weight management is not an approved Mounjaro indication.
Active IngredientTirzepatide, a dual GIP and GLP-1 receptor agonist.Tirzepatide, a dual GIP and GLP-1 receptor agonist. The same active ingredient as Zepbound.
Benefits
  • Weight Loss: Produces substantial average weight reduction in eligible adults.
  • Appetite Regulation: Helps reduce hunger and food intake.
  • Metabolic Health: May improve weight-related metabolic measures.
  • Sleep Apnea: Reduces obstructive sleep apnea severity in eligible adults with obesity.
  • Blood Sugar Control: Produces substantial reductions in blood glucose and HbA1c.
  • Weight Loss: Can produce clinically meaningful weight reduction in patients with type 2 diabetes.
  • Appetite Regulation: Helps reduce hunger and food intake.
  • Cardiovascular Health: Reduces major cardiovascular events in eligible adults with type 2 diabetes at high cardiovascular risk.
Potential Health Risks
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Gastrointestinal Reactions: Potentially severe digestive symptoms.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Eye Complications: Diabetic retinopathy requires appropriate monitoring.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
Weight Loss PotentialIn a 72-week clinical trial involving adults without diabetes, average body-weight reduction was approximately 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg. Results vary by dosage and patient population.In the SURPASS-2 trial involving adults with type 2 diabetes, tirzepatide produced approximately 7.6–11.2 kg (17–25 lb) of average weight loss over 40 weeks, depending on dose. Mounjaro is not approved specifically for weight management.
Administration
  • Injection: Subcutaneous injection once weekly.
  • Injection Sites: Abdomen, thigh, or upper arm.
  • Available Forms: Single-dose pens, single-dose vials, and single-patient-use KwikPen presentations.
  • Injection: Subcutaneous injection once weekly.
  • Injection Sites: Abdomen, thigh, or upper arm.
  • Available Forms: Prefilled injection pens, including available multidose pen presentations.
Dosing Considerations
  • Starting Dose: Typically 2.5 mg weekly for 4 weeks.
  • Dose Escalation: Increase to 5 mg weekly, with additional 2.5 mg increases after at least 4 weeks at the current dose when appropriate.
  • Weight Management Maintenance: 5 mg, 10 mg, or 15 mg weekly.
  • Sleep Apnea Maintenance: 10 mg or 15 mg weekly.
  • Maximum Dose: 15 mg weekly.
  • Starting Dose: Typically 2.5 mg weekly for 4 weeks.
  • Dose Escalation: Increase to 5 mg weekly, with additional 2.5 mg increases after at least 4 weeks at the current dose when appropriate.
  • Maintenance Dosing: Individualized according to blood sugar response and tolerability.
  • Maximum Adult Dose: 15 mg weekly.
Who May Benefit Most?Adults with obesity or qualifying overweight who need long-term weight management, including eligible patients with obesity-related obstructive sleep apnea.Patients aged 10 years and older with type 2 diabetes who need improved blood sugar control, including adults who may benefit from additional weight loss or meet its cardiovascular risk-reduction indication.
How Fast Does It Work?
  • Appetite: Changes may begin within the first several weeks.
  • Initial Weight Loss: May become noticeable within several weeks.
  • Substantial Weight Loss: Generally develops over several months, with major trials assessing outcomes at approximately 72 weeks.
  • Sleep Apnea: Major clinical trials assessed improvements after 52 weeks.
  • Blood Sugar: Improvements may begin within the first weeks of treatment.
  • HbA1c: Meaningful reductions generally develop over several weeks to months.
  • Weight Loss: May begin within several weeks and continue over subsequent months.
Potential Side Effects
  • Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
  • Other Effects: Fatigue, hair loss, and injection-site reactions.
  • Timing: Gastrointestinal symptoms frequently occur during dose escalation.
  • Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
  • Other Effects: Decreased appetite and possible injection-site reactions.
  • Timing: Gastrointestinal symptoms frequently occur during dose escalation.

Information Accuracy Disclaimer: Pricing, insurance coverage, medication availability, and other details may change over time. The information presented in this comparison reflects available information as of November 6, 2026. For the most current details, consult the medication manufacturers, your insurance provider, or a qualified healthcare professional.

Important: Zepbound and Mounjaro both contain tirzepatide and carry a boxed warning concerning thyroid C-cell tumors observed in rodents; whether they cause these tumors in humans is unknown. Neither should be used by patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). 

Zepbound and Mounjaro should not be taken together because they contain the same active ingredient. Treatment selection requires an individualized medical assessment.

Weight-loss evidence: In the SURMOUNT-1 clinical trial, tirzepatide administered as Zepbound produced average body-weight reductions of 15.0%, 19.5%, and 20.9% after 72 weeks at doses of 5 mg, 10 mg, and 15 mg, respectively, in adults with obesity or overweight without diabetes. 

In the SURPASS-2 clinical trial, tirzepatide administered as Mounjaro produced approximately 7.6–11.2 kg (17–25 lb) of average weight loss after 40 weeks in adults with type 2 diabetes, depending on dose. These results come from different patient populations and study designs, so they do not demonstrate that Zepbound causes more weight loss than Mounjaro at equivalent doses. Both medications contain the same active ingredient.

Sources:

Medical Disclaimer: This article is intended for informational and educational purposes only and provides a general comparison of Zepbound and Mounjaro. It is not a substitute for professional medical advice, diagnosis, or treatment.

The safety, effectiveness, and suitability of either medication depend on individual medical history, health conditions, and treatment goals. For a comprehensive evaluation and personalized treatment recommendations, consult a qualified healthcare provider before starting, changing, or discontinuing either medication.